Biogen to Seek Approval of Aducanumab for Early Alzheimer’s Based on New Analysis of Trials

Biogen to Seek Approval of Aducanumab for Early Alzheimer’s Based on New Analysis of Trials
Biogen is planning to seek approval for aducanumab, an injectable treatment under investigation for patients with early Alzheimer’s disease, following a new analysis of Phase 3 studies supporting meaningful benefits for patients' cognition and daily life abilities. After meeting with the U.S. Food and Drug Administration (FDA), Biogen plans to submit a Biologics License Application in early 2020. The company is also consulting with other regulatory authorities in other countries, including Europe and Japan. If accepted, aducanumab would become the first therapy to reduce the clinical decline of Alzheimer’s disease. The decision came after the analysis of a larger dataset of Phase 3 clinical trials ENGAGE (NCT02477800) and EMERGE (NCT02484547), showing that monthly vein infusions of aducanumab reduced the clinical decline of patients with early Alzheimer's. Both trials were halted in March after a monitoring committee analyzed data from the first 18 months of the studies and determined that aducanumab was not likely to produce meaningful benefits for patients. However, Biogen reconsidered when an
Subscribe or to access all post and page content.